10.50
-6.42%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Almirall
Its shares trade on BME under the ticker ALM.MC. It has been listed since 19 April 2007. In the fiscal year to 31 December 2025, it reported revenue of €1.11bn and net income of €46.2m. At that date it held total assets of €2.34bn and shareholders' equity of €1.49bn.
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company is headquartered in Barcelona, Barcelona. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Apr 2007
- Employees
- 1,786
- Website
- almirall.es ↗
Leadership
Pay as last reported
- Mr. Carlos Gallardo PiqueExecutive Chairman of the Board, Chief Executive Officer, since 2014€1.7m
- Mr. Paul RittmanPresident, General Manager - Almirall, US
- Mr. Enrique De Leyva PerezIndependent Vice Chairman of the Board€174,000
- Mr. Michael James McclellanChief Financial Officer
- Ms. Mercedes Diz LopezChief Marketing Officer
- Mr. Karl ZiegelbauerChief Scientific Officer
- Ms. Isabel Cristina GomezChief Legal Officer, General Counsel, Non-Member Vice-Secretary of the Board
- Mr. Pablo Divasson del FraileSenior Director - Investor Relations
- Mr. Paolo CioniniChief Commercial Officer, Europe & International, since 2023
- Mr. Esteve Conesa PanicotChief People & Culture Officer
- Mr. Eloi Crespo CerveraChief Industrial Operations Officer, since 2023
- Dr. Volker KoscielnyChief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 99
- Social
- 99
- Governance
- 37
- Direct emissions (scope 1)
- 6,154 t
- Energy emissions (scope 2)
- 4,868 t
- Value chain emissions (scope 3)
- 156,670 t
- Women in the workforce
- 54%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Almirall SA possesses several key strengths that contribute to its competitive advantage in the market. These include:
Weaknesses
- Despite its strengths, Almirall SA also faces certain weaknesses that may hinder its growth and performance. These include:
Opportunities
- Almirall SA has various opportunities in the market that it can capitalize on for future growth. These opportunities include:
Threats
- Almirall SA also faces several threats that may pose challenges to its business operations and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.